5 Reasons to Avoid Aurora Cannabis (TSX:ACB)(NYSE:ACB) in 2019

Investors are not looking to invest in Aurora Cannabis (TSX:ACB)(NYSE:ACB) because the business outlook remains questionable. There is likelihood that weed stocks can get hammered again.

| More on:
edit Woman calculating figures next to a laptop

Image source: Getty Images.

Reality has set in and replaced euphoria in the marijuana industry. Investors now doubt if the cannabis producers can actually deliver profits as promised. The shares of Aurora Cannabis (TSX:ACB)(NYSE:ACB) has risen nearly 76% on the TSX from the year-end closing price. But the risk of volatility hasn’t diminished.

Aurora Cannabis reported an exceptional first quarter to handily outplay closest rival Canopy Growth (TSX:WEED)(NYSE:CGC). The company’s market cap is just 60% of Canopy’s, but leads in the production department by a mile. If that’s the case, how come hitting the home run this year is still unsure?

Share dilution

In 2016, Aurora Cannabis went on a buying spree. The most notable among those is the buyout of ICC Labs in South America. Instead of paying in cash, the company paid via shares of stocks, convertible notes, warrants, and options. The sum total is one billion shares that dwarf the 16.2 million during its 2014 IPO.

With this scheme, share price valuation is difficult. It doesn’t sit well with investors. Aurora Cannabis is nothing more than a share dilution machine in a market that’s volatile and starting to bottom out.

Lower wholesale pricing

Aurora Cannabis is in the best position to scale in legalized marijuana market. Hitting sales targets won’t be an issue. However, lower wholesale pricing presents a huge problem. To illustrate this, the price per gram of dried cannabis dropped 21% year-over-year, which dented Aurora’s bottom line in 4Q 2018.

Also, Aurora didn’t realize the supposed higher margins from extracts, but succumbed to a price drop 25%. The company is posting higher sales, but the revenue per transaction is meager. If the trend of lower prices persists, it would be a big strain for the company and the industry in general.

No big firm partner but an activist investor to spur growth

Most of Aurora Cannabis’ competitors have partnered with big firms operating outside the cannabis sector. For its part, the company took in Nelson Peltz, founder of Triad Fund Management as a backer. This is not to belittle the track record of Peltz, however, who is known for turning companies around.

Still, the future success of Aurora lies squarely on Peltz’s shoulders. He might be the key to forge corporate partnerships that are missing so far. The strategic advisor needs to prove his mettle.

Another dilution move

Aurora Cannabis just announced another round of raising capital through the issuance of common equity, debt, warrants, subscription receipts, or a mix of the mentioned securities. The company defends the move to raise US$750 million as a long-term strategic measure. This would have a dilutive effect again.

The bases are loaded yet Aurora Cannabis would likely miss hitting the home run this year. Investors can’t interpret or make out exactly the strategy of the industry’s largest producer.

Until people can arrive at a sensible valuation, investing in Aurora Cannabis is highly speculative and a risky play. The glaring risks are the red flags.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »